Wells Fargo raised the firm’s price target on Sangamo (SGMO) to $3 from $1 and keeps an Equal Weight rating on the shares. The firm views partnership formation on Fabry program as well as full data from the pivotal study as key catalysts. Wells thinks upside to the stock will be driven by POC of wholly owned ZFP transcription factor neurology programs.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on SGMO:
- Sangamo Biosciences: Mine Safety Regulations Pose No Risk to Operations
- Sangamo price target raised to $9 from $3 at Barclays
- Sangamo Therapeutics Reports Strong Q3 2024 Growth
- Sangamo files $500M mixed securities shelf
- Sangamo reports Q3 EPS 4c, consensus (3c)
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
